National manufacturer of
immunobiological products in Russia

Vaccines

  • Influenza trivalent polymer subunit vaccine

    The vaccine is surface glycoproteins (hemagglutinin and neuraminidase) isolated from purified virions of influenza virus type A and B obtained from the virus-containing allantoic fluid of chicken embryos of clinically healthy chickens and diluted in phosphate buffered saline in combination with azoximer bromide (Polyoxidonium). The product does not contain a preservative or contains the preservative thiomersal (merthiolate).
  • Influenza vaccine (inactivated) SOVIGRIPP®

    The vaccine is surface glycoproteins (hemagglutinin and neuraminidase) isolated from purified virions of influenza virus types A and B obtained from the virus-containing allantoic fluid from chick embryos of clinically healthy chickens and diluted in phosphate-buffered saline in combination with adjuvant SOVIDON TM. The drug is available with the preservative thiomersal (merthiolate) or without a preservative. <br>
    The antigenic structure of the strains is varied each year according to guidelines of the WHO and the Commission on Influenza Vaccines and diagnostic strains of the Russian Ministry of Health.
  • Live tissue culture measles vaccine

    The live tissue culture measles vaccine, lyophilisate for the solution for subcutaneous injection, is prepared by cultivation of the vaccine strain of Leningrad-16 (L-16) measles virus on the primary culture of quail embryo cells.
  • Adsorbed pertussis-diphtheria-tetanus vaccine

    Administration of the preparation in accordance with the approved schedule leads to the development of specific immunity to pertussis, diphtheria and tetanus.
  • Live smallpox vaccine

    The live smallpox vaccine is a smallpox vaccine virus grown on scarified skin of calves, partially purified from bacterial flora by chlorhexidine digluconate. The smallpox vaccine contains 1 х 108 to 2 х 109 smallpox generating units (SGU) per ml.
  • Live combined typhus vaccine E

    A single injection of the vaccine is followed by the development of specific immunity for 15-30 days after vaccination.